Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

About ILUVIEN ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye.

An expert consensus was recently published by Kolomeyer and colleagues to gain insight into current understanding of the role of inflammation in diabetic macular edema pathophysiology and the ...

In the 36-month period immediately preceding ILUVIEN administration, patients received median 3.4 treatments per year. Thus, ILUVIEN treatment resulted in a 70.5% reduction in treatment burden.

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

The Iluvien brand has a potential global market worth $2 billion, Myers said. To date, Iluvien has been implanted in more than 1,500 eyes in the European Union, Myers said.

About ILUVIEN ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye.

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...